US FDA approves Lilly's breast cancer drug combo - Reuters
US FDA approves Lilly's breast cancer drug combo Reuters
Coverage by Political Leaning
See how different sides of the spectrum reported this story
Key People
No people linked to this story
Locations
All Coverage
<a href="https://news.google.com/rss/articles/CBMiogFBVV95cUxOTXlJZ0pUc3JoMHBCd2tEY2N5NWxsbHRXTFZFQ0RVaXRzV0UxZEM2TFNMcjVWUldkaUFaandZbHIxVmRqaUV3b2tPUzRKV3BPZ281TlRMblRGeTlZdjBrb1o3M0xnaHpEV1NyaExrdkFSSkFZcUJndVBQS2FGMHJwSXdJajlmZDV3amYzN2xRYVZZTWxlX1dscllPSjJDYWRxekE?oc=5" target="_blank">US FDA approves Lilly's breast cancer drug combo</a> <font color="#6f6f6f">Reuters</font>
Similar Stories
Related coverage based on topic and tags
US FDA approves AbbVie's drug for Parkinson's disease - reuters.com
US FDA approves AbbVie's drug for Parkinson's disease reuters.com
September 25, 2026 at 10:57 PMAstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination - Reuters
AstraZeneca, Daiichi Sankyo partner with Summit to test cancer drug combination Reuters
October 2, 2026 at 06:58 AMExperimental Lilly combination drug tops Zepbound in weight-loss trial - Reuters
Experimental Lilly combination drug tops Zepbound in weight-loss trial Reuters
September 30, 2026 at 05:34 PMLilly's experimental drug cuts weight by 21% in diabetes trial - reuters.com
Lilly's experimental drug cuts weight by 21% in diabetes trial reuters.com
September 29, 2026 at 10:15 PMMerck licenses SciBrunch cancer drug in deal worth up to $2.13 billion - Reuters
Merck licenses SciBrunch cancer drug in deal worth up to $2.13 billion Reuters
September 28, 2026 at 04:14 PMFDA seeks scientists and consumer representatives for advisory panels - reuters.com
FDA seeks scientists and consumer representatives for advisory panels reuters.com
September 30, 2026 at 08:30 PM